|
NCRNA00171 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.62169999998285E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.75954999999117E-05 |
| Normal-vs-Stage2 |
9.023700E-04 |
| Normal-vs-Stage3 |
6.82719999978154E-07 |
| Normal-vs-Stage4 |
1.22560000004324E-06 |
| Stage1-vs-Stage2 |
4.859800E-01 |
| Stage1-vs-Stage3 |
1.317440E-01 |
| Stage1-vs-Stage4 |
2.242400E-01 |
| Stage2-vs-Stage3 |
9.961700E-02 |
| Stage2-vs-Stage4 |
1.192420E-01 |
| Stage3-vs-Stage4 |
9.582600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.80439999997173E-06 |
| Normal-vs-AfricanAmerican |
1.038320E-03 |
| Normal-vs-Asian |
5.822600E-04 |
| Caucasian-vs-AfricanAmerican |
6.216800E-01 |
| Caucasian-vs-Asian |
2.653400E-01 |
| AfricanAmerican-vs-Asian |
7.692200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.6277000000352E-06 |
| Normal-vs-Female |
4.06389999996204E-06 |
| Male-vs-Female |
5.383600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.50590000000695E-06 |
| Normal-vs-Age(41-60Yrs) |
1.54484000000066E-05 |
| Normal-vs-Age(61-80Yrs) |
1.85869999999033E-05 |
| Normal-vs-Age(81-100Yrs) |
3.863800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.464600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.949200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.229600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.503200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.214000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.343000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.379240E-04 |
| Classical-VS-Follicular |
4.245400E-01 |
| Classical-VS-Other |
6.141200E-01 |
| Classical-VS-Normal |
2.09889999999158E-05 |
| Tall-VS-Follicular |
2.169200E-04 |
| Tall-VS-Other |
2.050000E-01 |
| Tall-VS-Normal |
3.63560004323915E-09 |
| Follicular-VS-Other |
5.135200E-01 |
| Follicular-VS-Normal |
5.158200E-04 |
| Other-VS-Normal |
3.989900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.3953000000041E-05 |
| Normal-vs-N1 |
2.48199999999255E-05 |
| N0-vs-N1 |
3.361800E-01 |
|
|
